A型肉毒毒素预防术后瘢痕:系统综述与荟萃分析
结果显示BoNT-A可改善临床医生复合评分、临床医生VAS及客观瘢痕宽度,延迟注射的合并效应可能大于即刻注射,即刻注射证据与患者报告结局仍不确定。
要点
- BoNT-A可降低客观瘢痕宽度(SMD -0.924,中等确定性证据)。
- 临床医生复合评分与VAS改善,但证据确定性为低至极低。
- 延迟注射合并效应可能大于即刻注射,但部位内时机研究结论冲突。
核心结论
- 中等确定性证据支持预防性BoNT-A减小客观瘢痕宽度,临床医生复合量表改善为低确定性证据。
- 探索性合并分析提示延迟注射效应可能大于即刻注射,但同一部位内直接比较时机的原始研究结论相互冲突。
- 即刻注射证据与患者报告结局仍不确定,4-10 U/cm范围内跨研究剂量递增未见额外获益。
研究设计与样本
- 系统综述与荟萃分析,检索四个数据库至2026年1月,纳入围术期或术后注射BoNT-A的对照试验。
- 通过亚组分析与荟萃回归考察注射时机、剂量密度与解剖部位对效应的修饰作用,注射层次实践仅作描述性总结。
主要发现
- 临床医生复合评分改善:SMD -0.864(95% CI -1.137至-0.591),低确定性。
- 临床医生VAS改善:SMD -0.951(95% CI -1.468至-0.434),极低确定性。
- 客观瘢痕宽度减小:SMD -0.924(95% CI -1.119至-0.728),中等确定性。
- 探索性合并分析:延迟注射SMD -1.240(中等确定性),即刻注射SMD -0.559(低确定性)。
- 时机与解剖部位共同解释81%的异质性(P = .0008),胸部效应最大、面部精细部位效应最小。
关键数值与推荐
- 客观瘢痕宽度:SMD -0.924(95% CI -1.119至-0.728),中等确定性。
- 临床医生复合评分:SMD -0.864(95% CI -1.137至-0.591),低确定性。
- 临床医生VAS:SMD -0.951(95% CI -1.468至-0.434),极低确定性。
- 延迟注射SMD -1.240(中等确定性)对比即刻注射SMD -0.559(低确定性),来自原始研究时机分组的探索性合并分析。
- 跨研究剂量在4-10 U/cm范围内递增未显示额外获益。
临床怎么用
- 可将预防性BoNT-A作为减小术后瘢痕宽度的辅助手段,尤其适用于胸部等效应较大的部位。
- 注射时机与剂量密度尚无统一最优方案,延迟注射的潜在优势需结合部位内直接比较研究谨慎解读。
- 面部精细部位效应较小、即刻注射证据不足,决策时应个体化并与患者充分沟通证据确定性。
局限性
- 即刻注射证据与患者报告结局仍不确定,相关结论受限。
- 注射层次实践仅作描述性总结,无法就进针平面给出量化推荐。
- 时机效应主要来自研究层面的探索性合并分析,同一部位内直接比较时机的原始研究结论相互冲突。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Postoperative scars may impair quality of life. Prophylactic botulinum toxin type A (BoNT-A) may reduce scarring, but optimal timing, dose density, injection plane, and anatomic indications remain uncertain. This systematic review and meta-analysis evaluated prophylactic BoNT-A for postoperative scar prevention and examined effect modification by timing, dose density, and anatomic site; injection-plane practices were summarized descriptively. Four databases were searched through January 2026 for comparative trials of perioperative or postoperative BoNT-A administration. Random-effects meta-analysis used standardized mean differences (SMDs); subgroup analyses and meta-regression examined timing, dose density, and anatomic site. Seventeen studies (656 treatment sites; 456 participants) were included. BoNT-A improved clinician composite scores (SMD, -0.864; 95% CI, -1.137 to -0.591; low certainty), clinician VAS (SMD, -0.951; 95% CI, -1.468 to -0.434; very low certainty), and objective scar width (SMD, -0.924; 95% CI, -1.119 to -0.728; moderate certainty). Exploratory pooled analyses using the original study-level timing assignments suggested a larger effect with delayed injection (SMD, -1.240; moderate certainty) than with immediate injection (SMD, -0.559; low certainty). Timing and anatomic site jointly accounted for 81% of heterogeneity (P = .0008), with effects largest in chest and smallest in fine facial sites. Moderate-certainty evidence supports reduced objective scar width; clinician composite scales improved with low certainty. Pooled clinician-composite analyses suggested larger effects with delayed injection, although direct within-site timing studies have reported conflicting findings. Immediate-injection evidence and patient-reported outcomes remain uncertain, and cross-study dose escalation within 4-10 U/cm was not associated with additional benefit.
引用
- Ho YH, Chang TW, Hsu CW, et al. Botulinum Toxin Type A for Postoperative Scar Prevention: A Systematic Review and Meta-analysis. Aesthet Surg J. 2026. PMID: 42767642. doi:10.1093/asj/sjag204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。